Organon Q3 2024 Earnings Report
Key Takeaways
Organon reported a 4% increase in total revenue to $1.582 billion for the third quarter of 2024. Growth was primarily driven by Women's Health and Biosimilars segments. The company maintained disciplined operating costs, contributing to Adjusted EBITDA growth and progress towards achieving $1 billion in free cash flow for the full year.
Total revenue increased by 4% to $1.582 billion, up 5% excluding foreign exchange impacts.
Women's Health revenue grew by 5%, driven by Nexplanon's 11% growth ex-FX.
Biosimilars revenue increased by 16%, boosted by the uptake of Hadlima in the U.S.
Established Brands revenue grew by 2%, supported by Emgality licensing and growth in China.
Organon
Organon
Forward Guidance
Organon's full year 2024 financial guidance is presented on a non-GAAP basis, except revenue.